2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00069186
(ClinicalTrials.gov)
June 200317/9/2003Study of Creatine Monohydrate in Patients With Amyotrophic Lateral SclerosisA Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)Drug: Creatine MonohydrateThe Avicena GroupNULLActive, not recruiting21 Years80 YearsBoth107Phase 3United States
2NCT00070993
(ClinicalTrials.gov)
December 20029/10/2003Creatine for the Treatment of Amyotrophic Lateral SclerosisClinical Trial of Creatine in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: creatine monohydrateNational Center for Complementary and Integrative Health (NCCIH)Office of Dietary Supplements (ODS)Completed21 Years80 YearsBoth110Phase 2United States